Related Experiment Video
Updated: Jul 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Biologics in the treatment of psoriasis]
Joachim Dissemond1, Stephan Grabbe
1Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen. joachimdissemond@hotmail.com
Abstract:
Currently, psoriasis is seen as a T-cell-mediated autoimmune disease that is characterized by an increased expression of pro-inflammatory cytokines. The clarification of this pathogenetic cascade uncovered a number of points of departure for the development of causal therapy and led to the introduction of new medications--the so-called biologics. The following have already been approved in Germany: infliximab, etanercept, efalizumab and adalimumab. These are described, and their advantages and disadvantages in the clinical setting are discussed.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...